Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga Citrate PET/MRI for Fever of Unknown Origin
NCT04139395Phase 3Withdrawn
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium-68 citrate in fever of unknown origin (FUO). Primary endpoint: Uptake detected by investigational imaging agent at 12 months. Planned start Jan 2019; status: withdrawn.
02
Drugs
gallium-68 citrate
03
Conditions
fever of unknown origin (FUO)
Beyond the preview
Go deeper on NCT04139395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139395.